{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T21:14:14Z","timestamp":1766870054098,"version":"3.41.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011367","name":"Key Laboratory of Marine Materials and Related Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004008","name":"National Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpet.2025.103594","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:22:27Z","timestamp":1745972547000},"page":"103594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhanced negative modulation of urotensin II on cardiac function and [Ca2+]i regulation in a diabetic rat model: Insights into molecular and cellular mechanisms"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-894X","authenticated-orcid":false,"given":"Xiaowei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8450-5644","authenticated-orcid":false,"given":"Jing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0253-8192","authenticated-orcid":false,"given":"Zhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-9549","authenticated-orcid":false,"given":"Tiankai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-6868","authenticated-orcid":false,"given":"Heng-Jie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-3793","authenticated-orcid":false,"given":"Che Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103594_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2125.2002.t01-1-01704.x","article-title":"No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans","volume":"54","author":"Affolter","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1942086","article-title":"Calcium homeostasis in ventricular myocytes of diabetic cardiomyopathy","volume":"2020","author":"Al Kury","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jpet.2025.103594_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","article-title":"Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14","volume":"401","author":"Ames","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jpet.2025.103594_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00006676-199301000-00011","article-title":"Long-term diabetogenic effect of streptozotocin in rats","volume":"8","author":"Ar'Rajab","year":"1993","journal-title":"Pancreas"},{"key":"10.1016\/j.jpet.2025.103594_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fendo.2012.00165","article-title":"A closer look at the role of urotensin II in the metabolic syndrome","volume":"3","author":"Barrette","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jpet.2025.103594_bib6","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1161\/CIRCULATIONAHA.106.679597","article-title":"Diabetic cardiomyopathy revisited","volume":"115","author":"Boudina","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103594_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1196\/annals.1372.018","article-title":"Effects of streptozotocin-induced diabetes on contraction and calcium transport in rat ventricular cardiomyocytes","volume":"1084","author":"Bracken","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jpet.2025.103594_bib8","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jpet.2025.103594_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12613-y","article-title":"Urotensin II exerts pressor effects by stimulating renin and aldosterone synthase gene expression","volume":"7","author":"Caroccia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2025.103594_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-201x.1999.00547.x","article-title":"Decrease in sodium-calcium exchange and calcium currents in diabetic rat ventricular myocytes","volume":"166","author":"Chattou","year":"1999","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.jpet.2025.103594_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2012.01.034","article-title":"Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK","volume":"680","author":"Chen","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/CIRCULATIONAHA.105.596494","article-title":"Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy","volume":"114","author":"Cheng","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103594_bib13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.RES.78.5.880","article-title":"Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure","volume":"78","author":"Cheng","year":"1996","journal-title":"Circ Res"},{"issue":"Suppl 1","key":"10.1016\/j.jpet.2025.103594_bib14","article-title":"The role and mechanism of chronic Ca2+ calmodulin-dependent protein kinase II inhibition in a mouse model of diabetic cardiomyopathy","volume":"140","author":"Cheng","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103594_bib15","doi-asserted-by":"crossref","first-page":"H1398","DOI":"10.1152\/ajpheart.00313.2002","article-title":"Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in type 1 diabetic rats","volume":"283","author":"Choi","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jpet.2025.103594_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2006.10.008","article-title":"Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy","volume":"22","author":"Dai","year":"2008","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jpet.2025.103594_bib17","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","article-title":"Congestive heart failure and expression of myocardial urotensin II","volume":"359","author":"Douglas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jpet.2025.103594_bib18","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.85.6.2132","article-title":"Are contraction and relaxation coupled in patients with and without congestive heart failure?","volume":"85","author":"Eichhorn","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103594_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00210-007-0180-8","article-title":"Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling","volume":"376","author":"Fontes-Sousa","year":"2007","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.33549\/physiolres.931524","article-title":"Urotensin II-induced increase in myocardial distensibility is modulated by angiotensin II and endothelin-1","volume":"58","author":"Fontes-Sousa","year":"2009","journal-title":"Physiol Res"},{"key":"10.1016\/j.jpet.2025.103594_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.bjp.0705954","article-title":"Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response","volume":"143","author":"Gardiner","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib22","first-page":"274","article-title":"Streptozotocin as a tool for induction of rat models of diabetes: a practical guide","volume":"22","author":"Ghasemi","year":"2023","journal-title":"EXCLI J"},{"key":"10.1016\/j.jpet.2025.103594_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002727","article-title":"Developing new treatments for heart failure: focus on the heart","volume":"9","author":"Gheorghiade","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jpet.2025.103594_bib24","doi-asserted-by":"crossref","first-page":"12482","DOI":"10.3390\/ijms160612482","article-title":"Urotensin II protects cardiomyocytes from apoptosis induced by oxidative stress through the CSE\/H2S pathway","volume":"16","author":"Gong","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103594_bib25","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1152\/japplphysiol.00540.2004","article-title":"Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat","volume":"97","author":"Gong","year":"2004","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.jpet.2025.103594_bib26","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.3390\/ijms22115973","article-title":"The mystery of diabetic cardiomyopathy: from early concepts and underlying mechanisms to novel therapeutic possibilities","volume":"22","author":"Grubi\u0107 Rotkvi\u0107","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103594_bib27","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.peptides.2010.04.009","article-title":"Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt\/GSK-3beta signaling pathway","volume":"31","author":"Gruson","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.jpet.2025.103594_bib28","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.peptides.2005.11.019","article-title":"Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers","volume":"27","author":"Gruson","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.jpet.2025.103594_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1751-7176.2010.00336.x","article-title":"Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype","volume":"12","author":"Gruson","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jpet.2025.103594_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1139\/y03-004","article-title":"Effect of human urotensin-II infusion on hemodynamics and cardiac function","volume":"81","author":"Hassan","year":"2003","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00210-012-0728-0","article-title":"In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands","volume":"385","author":"Hunt","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib32","doi-asserted-by":"crossref","first-page":"R1787","DOI":"10.1152\/ajpregu.00059.2007","article-title":"Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes","volume":"293","author":"Lacombe","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jpet.2025.103594_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2018.03.066","article-title":"Critical role of the chymase\/angiotensin-(1-12) axis in modulating cardiomyocyte contractility","volume":"264","author":"Li","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jpet.2025.103594_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijcard.2019.09.004","article-title":"Reversal of angiotensin-(1-12)-caused positive modulation on left ventricular contractile performance in heart failure: assessment by pressure-volume analysis","volume":"301","author":"Li","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jpet.2025.103594_bib35","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/01.CIR.85.6.2326","article-title":"Enhanced load dependence of relaxation in heart failure. Clinical implications","volume":"85","author":"Little","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103594_bib36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.120.000361","article-title":"Chronic Ca2+\/calmodulin-dependent protein kinase II inhibition rescues advanced heart failure","volume":"377","author":"Liu","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103594_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1475-2840-13-68","article-title":"Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1","volume":"13","author":"Moore","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"10.1016\/j.jpet.2025.103594_bib38","first-page":"A26","article-title":"Urotensin II inhibits left ventricular and myocyte contractile performance and [Ca2+] (i) transient: normal vs CHF","volume":"106","author":"Morimoto","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103594_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111056","article-title":"Evidence for heterodimerization and functional interaction of the urotensin II and the angiotensin II type 1 receptors","volume":"116","author":"Nassour","year":"2024","journal-title":"Cell Signal"},{"key":"10.1016\/j.jpet.2025.103594_bib40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/FJC.0000000000000618","article-title":"A novel and highly potent urotensin II receptor antagonist inhibits urotensin II-induced pressure response in mice","volume":"73","author":"Nishi","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10863-013-9514-z","article-title":"Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart","volume":"45","author":"Ozturk","year":"2013","journal-title":"J Bioenerg Biomembr"},{"key":"10.1016\/j.jpet.2025.103594_bib42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000499880","article-title":"Urotensin II induces mice skeletal muscle atrophy associated with enhanced autophagy and inhibited irisin precursor (fibronectin type III domain containing 5) expression in chronic renal failure","volume":"44","author":"Pan","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.jpet.2025.103594_bib43","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjp.0705555","article-title":"Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta","volume":"140","author":"Patacchini","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1099\/mic.0.082610-0","article-title":"Streptozotocin-induced type-1-diabetes disease onset in Sprague-Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity","volume":"161","author":"Patterson","year":"2015","journal-title":"Microbiology (Reading)"},{"key":"10.1016\/j.jpet.2025.103594_bib45","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.drudis.2019.08.005","article-title":"Novel insights into the role of urotensin II in cardiovascular disease","volume":"24","author":"Pereira-Castro","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jpet.2025.103594_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCHEARTFAILURE.107.748343","article-title":"Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium","volume":"2","author":"Quaile","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jpet.2025.103594_bib47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/biomedicines12040765","article-title":"Diabetic cardiomyopathy\u2014from basics through diagnosis to treatment","volume":"12","author":"Radzioch","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jpet.2025.103594_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2019.09.052","article-title":"Angiotensin-(1-12)\/chymase axis modulates cardiomyocyte L-type calcium currents in rats expressing human angiotensinogen","volume":"297","author":"Reyes","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jpet.2025.103594_bib49","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jpet.2025.103594_bib50","doi-asserted-by":"crossref","first-page":"R1156","DOI":"10.1152\/ajpregu.00706.2009","article-title":"Role of urotensin II in health and disease","volume":"298","author":"Ross","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jpet.2025.103594_bib51","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/VHRM.S1983","article-title":"Urotensin II in cardiovascular regulation","volume":"4","author":"Russell","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jpet.2025.103594_bib52","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cardiores.2004.05.009","article-title":"Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart","volume":"63","author":"Russell","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jpet.2025.103594_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.bjp.0703811","article-title":"Cardiostimulant effects of urotensin-II in human heart in vitro","volume":"132","author":"Russell","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijcard.2015.11.040","article-title":"Overexpression myocardial inducible nitric oxide synthase exacerbates cardiac dysfunction and beta-adrenergic desensitization in experimental hypothyroidism","volume":"204","author":"Shao","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jpet.2025.103594_bib55","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2125.2009.03480.x","article-title":"Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with type 2 diabetes mellitus","volume":"68","author":"Sidharta","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib56","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13034","article-title":"Regional effects of streptozotocin-induced diabetes on shortening and calcium transport in epicardial and endocardial myocytes from rat left ventricle","volume":"4","author":"Smail","year":"2016","journal-title":"Physiol Rep"},{"key":"10.1016\/j.jpet.2025.103594_bib57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjmed.2024.10.026","article-title":"Diabetic cardiomyopathy: what clinicians should know","volume":"138","author":"Smati","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.jpet.2025.103594_bib58","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/cvr\/28.8.1243","article-title":"Cellular and molecular alterations in the beta adrenergic system with cardiomyopathy induced by tachycardia","volume":"28","author":"Spinale","year":"1994","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jpet.2025.103594_bib59","article-title":"Increased CaMKII activation and contrast changes of cardiac \u03b21-and \u03b23-adrenergic signaling pathways in a humanized angiotensinogen model of hypertension","volume":"9","author":"Sun","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jpet.2025.103594_bib60","doi-asserted-by":"crossref","first-page":"E1234","DOI":"10.1152\/ajpendo.90672.2008","article-title":"Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction","volume":"295","author":"Tian","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jpet.2025.103594_bib61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fphys.2018.00453","article-title":"Diabetic cardiomyopathy: impact of biological sex on disease development and molecular signatures","volume":"9","author":"Toedebusch","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.jpet.2025.103594_bib73","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.peptides.2004.06.024","article-title":"Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy","volume":"25","author":"Totsune","year":"2004","journal-title":"Peptides"},{"key":"10.1016\/j.jpet.2025.103594_bib62","doi-asserted-by":"crossref","first-page":"H608","DOI":"10.1152\/ajpheart.00942.2009","article-title":"Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats","volume":"298","author":"Tran","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jpet.2025.103594_bib63","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2011.00038","article-title":"Potential clinical implications of the urotensin II receptor antagonists","volume":"2","author":"Tsoukas","year":"2011","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2025.103594_bib64","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.RES.0000084382.64418.BC","article-title":"Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy","volume":"93","author":"Tzanidis","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jpet.2025.103594_bib65","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00125-013-2837-9","article-title":"Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes","volume":"56","author":"Watson","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jpet.2025.103594_bib66","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1096\/fj.13-236471","article-title":"Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice","volume":"28","author":"You","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.jpet.2025.103594_bib67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0008-6363(97)00034-5","article-title":"Intracellular calcium levels are unchanged in the diabetic heart","volume":"34","author":"Yu","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jpet.2025.103594_bib68","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12632","article-title":"Characterization of L-type calcium channel activity in atrioventricular nodal myocytes from rats with streptozotocin-induced diabetes mellitus","volume":"3","author":"Yuill","year":"2015","journal-title":"Physiol Rep"},{"key":"10.1016\/j.jpet.2025.103594_bib69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijcard.2017.01.071","article-title":"Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure","volume":"236","author":"Zhang","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jpet.2025.103594_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119955","article-title":"Chronic GPR30 agonist therapy causes restoration of normal cardiac functional performance in a male mouse model of progressive heart failure: Insights into cellular mechanisms","volume":"285","author":"Zhang","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.jpet.2025.103594_bib71","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1074\/jbc.M114.615021","article-title":"Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the \u03b2\u03b3 subunits of Gi\/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C \u03b21 isoform","volume":"290","author":"Zhang","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103594_bib72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1753944715587424","article-title":"Modulation of cardiac L-type Ca2+ current by angiotensin-(1-7): normal versus heart failure","volume":"9","author":"Zhou","year":"2015","journal-title":"Ther Adv Cardiovasc Dis"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:18:05Z","timestamp":1751019485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022356525398071"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103594","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced negative modulation of urotensin II on cardiac function and [Ca2+]i regulation in a diabetic rat model: Insights into molecular and cellular mechanisms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103594"}}